Bactericidal, antibiotic acne topical treatment reduces inflammatory lesions

Vyome Therapeutics reported results from two clinical trials of its anti-acne candidate VB-1953; the bactericidal, antibiotic topical gel kills sensitive and resistant strains of C.acnes infection, and has been shown to reduce inflammation, at the Society for Investigative Dermatology annual meeting in Chicago. 

“Data presented at [the Society for Investigative Dermatology meeting] demonstrated that VB-1953 was not only capable of significantly reducing inflammatory lesions in moderate to severe acne, but also showed the ability to reduce inflammatory lesions of those patients who are non-responders or are resistant to the first-line antibiotic treatment, clindamycin,” according to the release.

In a proof of concept, double-blind, vehicle-controlled randomized study, topical VB-1953 2% gel was evaluated over 12 weeks in adult patients with moderate to severe facial acne vulgaris.

The researchers found that with 12 weeks of twice-daily treatment a significant reduction of 71.4% in inflammatory lesions (P < .05) was reported. Additionally, in as early as 8 weeks after treatment, researchers reported an approximate 60% reduction in inflammatory lesions (P < .01 vs. vehicle).

In the other clinical trial, Vyome evaluated VB-1953 in antibiotic-resistant P. acnes strains. Treatment twice daily resulted in a reduction in absolute inflammatory lesions from a mean baseline of 34.4 to 16.7 lesions at week 12 (P < .001). Resistant bacteria were reduced by a mean of 94.3% (P < .05) within 4 weeks of treatment.

 

Editor's note: We updated this story to reflect minor changes to the initial press release and removed language about primary endpoints.

Vyome Therapeutics reported results from two clinical trials of its anti-acne candidate VB-1953; the bactericidal, antibiotic topical gel kills sensitive and resistant strains of C.acnes infection, and has been shown to reduce inflammation, at the Society for Investigative Dermatology annual meeting in Chicago. 

“Data presented at [the Society for Investigative Dermatology meeting] demonstrated that VB-1953 was not only capable of significantly reducing inflammatory lesions in moderate to severe acne, but also showed the ability to reduce inflammatory lesions of those patients who are non-responders or are resistant to the first-line antibiotic treatment, clindamycin,” according to the release.

In a proof of concept, double-blind, vehicle-controlled randomized study, topical VB-1953 2% gel was evaluated over 12 weeks in adult patients with moderate to severe facial acne vulgaris.

The researchers found that with 12 weeks of twice-daily treatment a significant reduction of 71.4% in inflammatory lesions (P < .05) was reported. Additionally, in as early as 8 weeks after treatment, researchers reported an approximate 60% reduction in inflammatory lesions (P < .01 vs. vehicle).

In the other clinical trial, Vyome evaluated VB-1953 in antibiotic-resistant P. acnes strains. Treatment twice daily resulted in a reduction in absolute inflammatory lesions from a mean baseline of 34.4 to 16.7 lesions at week 12 (P < .001). Resistant bacteria were reduced by a mean of 94.3% (P < .05) within 4 weeks of treatment.

 

Editor's note: We updated this story to reflect minor changes to the initial press release and removed language about primary endpoints.